Summary
All claims about sexual dysfunction comparisons and incidence are not supported by the FDA-approved prescribing information provided. The label lists adverse reactions (including hypersenstivity, suicidality, serotonin syndrome, bleeding risk, mania/hypomania, discontinuation symptoms, glaucoma risk, hyponatremia) and notes on clinical studies for Major Depressive Disorder, but does not contain the sexual dysfunction comparative data or real-world/in analyses claims cited.
Category Scores
Accurate Statements
Unsupported Statements
Trintellix (vortioxetine) causes less sexual dysfunction than Lexapro (escitalopram) in clinical studies.
Not present in label; no comparative sexual dysfunction data between vortioxetine and escitalopram.
A head-to-head trial (FOCUS study) found sexual dysfunction rates of 16-34% with Trintellix (5-20 mg doses) versus 14-20% with placebo.
Not present in label; no head-to-head sexual dysfunction data comparing vortioxetine to placebo in label.
There are higher implied rates for SSRIs like Lexapro based on class data.
Not present in label; no class-wide SSRI sexual dysfunction data in label.
Pooled analyses show Trintellix's sexual dysfunction incidence at 2-4% above placebo.
Not present in label; no pooled analyses of sexual dysfunction incidence in label.
Lexapro hits 5-10% above placebo.
Not present in label; no placebo-adjusted rates for Lexapro in label.
There are changes in sex drive scores 50-70% lower for Trintellix.
Not present in label; no quantified changes in sexual desire scores for vortioxetine in label.
FOCUS and CONNECT trials: Trintellix 10-20 mg showed no worsening (or slight improvement) in sexual function versus baseline.
Not present in label; sexual function data from FOCUS/CONNECT not provided in label.
FOCUS and CONNECT trials: SSRIs like Lexapro worsened sexual function.
Not present in label; no comparative sexual function data from these trials in label.
Meta-analyses: 5,690 patients across 13 RCTs; Trintellix's odds ratio for dysfunction was 1.03 (near placebo) vs. 1.73-2.5 for SSRIs.
Not present in label; no meta-analytic data on sexual dysfunction in label.
Real-world data from registries aligns, with 20-30% fewer complaints for Trintellix switchers from SSRIs.
Not present in label; no real-world registry data on sexual dysfunction in label.
Patients switching from Lexapro to Trintellix often see 40-60% resolution of sexual issues within 4-8 weeks.
Not present in label; no switching outcome data in label.
10-15% still face problems.
Not present in label; no quantified residual sexual dysfunction data in label.
Risk factors like higher doses (Lexapro >10 mg) or female gender amplify SSRI effects more.
Not present in label; no SSRI-dose or gender-based amplification data for sexual dysfunction in label.
Taper Lexapro slowly to avoid withdrawal.
Not present in label; tapering guidance specific to Lexapro withdrawal is not described in label here.
Trintellix onset takes 1-2 weeks.
Not present in label; time to onset data for vortioxetine not provided in label excerpt.
Bupropion (Wellbutrin) has the lowest rates (<5% dysfunction, often improves it) but less efficacy for anxiety.
Not present in label; no comparative sexual dysfunction data for bupropion in label.
Mirtazapine or vilazodone offer middle-ground profiles similar to Trintellix.
Not present in label; no comparative sexual dysfunction profiles for mirtazapine or vilazodone in label.
Add-ons like bupropion (150 mg) or sildenafil resolve SSRI issues in 60-80% without switching.
Not present in label; no augmentation data for sexual dysfunction in label.
Trintellix adds agonist/antagonist effects at 5-HT1A/B/D receptors, boosting dopamine/norepinephrine indirectly.
Not present in label; mechanism details described beyond label scope.
Lexapro blocks serotonin reuptake strongly, which can raise prolactin and disrupt dopamine signaling, hitting libido, arousal, and orgasm hardest.
Not present in label; no such mechanistic claims regarding libido in label.
This multimodal action explains the gap: Trintellix scores better on ASEX scales by 2-4 points versus SSRIs.
Not present in label; no ASEX-scale data in label.
Contradictions
Important Omissions
Label does not discuss sexual function outcomes, comparative efficacy/safety for sexual dysfunction, or real-world data related to vortioxetine versus SSRIs.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The claims do not reflect the label's stated adverse reactions; no new safety risk is identified by these unsupported statements.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Not Aligned
Primary Issue
Claims about sexual dysfunction are not supported by FDA label.
Suggested Improvement
Limit claims to information explicitly stated or clearly derived from the FDA-approved label; avoid extrapolations or non-labeled comparisons.